735 results about "Psychiatry" patented technology

The invention discloses an intelligent intervention system for children with autism spectrum disorder based on multi-modal neural feedback, which comprises a multi-modal physiological signal acquisition module for acquiring electroencephalogram signals of a target child in real time and generating an original physiological signal set; the multi-modal fusion analysis module receives the original physiological signal set and generates a comprehensive evaluation signal representing the current neurocognitive state and the emotion awakening level of the child; the self-adaptive decision control module receives the comprehensive evaluation signal and generates a self-adaptive control signal containing a neural feedback parameter adjustment instruction and a game interaction strategy instruction; the neural feedback intervention module receives the neural feedback parameter adjustment instruction and generates an adaptive neural feedback stimulation signal to act on the child; and the intelligent interactive game module receives a game interactive strategy instruction and dynamically adjusts game scene contents. The intelligent intervention system for children with autism spectrum disorder based on multi-modal neural feedback can solve the problems of poor individual adaptation of autism intervention, multi-modal data splitting and lack of dynamic adjustment.

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

The invention belongs to the technical field of cognitive impairment intervention evaluation, and particularly relates to an evaluation system and method applied to cognitive impairment intervention. According to the method, the cognitive state is evaluated and the training tasks are allocated based on the real data of the user in the natural life scene, so that the one-sidedness of only depending on a laboratory or one-time evaluation is avoided, the training and intervention are closer to the real demand and life situation of the user, and the training efficiency is improved through multi-source data fusion. The influence of single signal noise or accidental fluctuation on judgment is reduced, the robustness and objectivity of evaluation are improved, indexes such as cognitive performance, intervention indexes and deviation degree are numeralized, long-term tracking and transverse comparison of the effects of different intervention measures are facilitated, interpretable quantitative evidences are provided for clinical personnel, and the accuracy of evaluation is improved. Intervention indexes are calculated in real time, intervention measures are automatically adjusted or reselected according to feedback results, and a quick-response closed-loop system is formed, so that the time from problem discovery to effective intervention is shortened, and the intervention conversion rate is increased.

The present disclosure relates to child restraint systems and components of child restraint systems, for example child seats like a toddler seat and an infant seat, support bases of child seats, in particular support bases that are fixable on a vehicle seat and which bases may be an integral part of a child seat or which may be configured such that a child seat is releasably couplable to them.

The invention relates to the technical field of health data analysis, in particular to a traditional Chinese medicine children physique and pathology analysis system which comprises an electroencephalogram signal sensing module, a phase deviation feature extraction module, a wave band energy delay analysis module, a physique type judgment module and a pathology risk prediction module. According to the method, frequency domain analysis and phase offset calculation are carried out on electroencephalogram signals, accurate quantification of sleep state sign characteristics is achieved, the sequential relation between the phase change trend and wave band energy is captured, a dynamic characteristic combination capable of reflecting the rhythm transfer rule is constructed, the separability of physique differences is enhanced in a nonlinear mapping mode, and the accuracy of the physique differences is improved. A classification process is kept stable in a high-dimensional space, and a multi-factor prediction system is formed by combining indexes such as energy delay and phase anomaly, so that health state assessment has continuity and sensitivity, risk change can be identified in an early stage, and refined judgment of children's pathological tendency and improvement of result robustness are realized.

The invention discloses a premature infant action intention recognition method. The method comprises the following steps: S1, data acquisition; s2, data preprocessing; s3, extracting data features; s4, performing feature time sequence processing; and S5, judging the action intention. The premature infant action intention recognition method has the beneficial effects that the distinction degree of the action intention is improved, the recognition accuracy is improved, the influence of the development level is eliminated, personalized recognition is realized, individual differences of infants are adapted, the requirements of tender skins and free activities of the infants are met, a therapist can be effectively guided to adjust a training scheme in time, and the training efficiency is improved. And parents can be effectively assisted in judging whether training actions reach the standard or not.

The invention relates to pediococcus acidilactici, in particular to pediococcus acidilactici TCI550 with the preservation number of DSM34536, and the pediococcus acidilactici TCI550 has the preservation number of DSM34536. In addition, the pediococcus acidilactici TCI550 and / or metabolites thereof can be suitable for preparing a composition for nerve health care and / or cognition improvement.

Methods of treating a subject for a dissociative disorder and methods of screening agents for the ability to modulate dissociative and associative states in a subject are provided. In particular, agents that alter rhythmic neural activity in the posteromedial cortex can be used to modulate dissociative and associative states in a subject.

The invention discloses an AI psychological counseling method and system for generating an emotional map and a differentiation report, and relates to the technical field of artificial intelligence and psychology crossing. The invention discloses an AI psychological counseling method and system for generating an emotional map and a differentiated report. Through interaction of voice and characters, a visual emotional map is generated, personalized action suggestions are generated, and a visitor report or a psychological counselor report is generated. According to the method, a visual emotional map is generated through voice and character analysis, changes in the emotional map can be seen more visually, meanwhile, a proper psychological AI model is adapted, personalized action suggestions and corresponding related reports are generated, fine emotional fluctuations can be effectively captured through the accurate voice and character capturing capacity, and therefore the emotional effect is improved. A multi-dimensional emotion analysis model is arranged in the system, emotion fluctuation is monitored in real time, a detailed emotion change trend chart is generated, and the scientific basis is provided for psychological counseling.

The present inventive concept provides methods of determining whether a subject has cortical or cerebral visual impairment (CVI) as well as determining whether the subject has a traumatic brain injury thereby allowing treatment for these conditions. The present inventive concept also provides a standardized method for assessing pediatric or adolescent visual acuity.

Provided is a medicament for treating a disease related to motor neuron injury. The medicament comprises: a circular RNA having a circBank ID of hsa_circPTPRN2_018, and a proper diagnosis module and a drug carrier. Also provided is use of a circular RNA in preparing a medicament for diagnosing and treating a disease related to motor neuron injury.

A method for predicting early onset of mental health issues in work environments using artificial intelligence (AI) comprising: a) collecting data from two sources: (1) derived from employee survey an

The objective of the present invention is to provide an Alzheimer-type dementia suppressant that is safe and thus can be administered daily and utilized as a health food and by which Alzheimer-type dementia can be suppressed, and a method for producing the Alzheimer-type dementia suppressant. In addition, the objective of the present invention is also to provide a use of an aboveground part of Sesamum indicum or an extract thereof for suppressing Alzheimer-type dementia, and a method for suppressing Alzheimer-type dementia. The Alzheimer-type dementia suppressant according to the present invention is characterized in comprising an aboveground part of Sesamum indicum or an extract thereof as an active ingredient.

The problem addressed by the invention is that of providing a new means for improving complex attention, cognitive flexibility and / or execution functions. There is provided a composition for improving at least one selected from the group consisting of complex attention, cognitive flexibility and executive function, the composition comprising bifidobacteria and a water-soluble dietary fiber.

The invention discloses an SRCIN1 gene therapy vector for autism treatment and application of the SRCIN1 gene therapy vector, and relates to the field of autism treatment. The vector is a lentiviral vector and comprises an overexpression sequence of an SRCIN1 gene, the overexpression sequence is pSLentiti-CMV-Srcin1-P2A-EGFP-WPRE, and the titer of the overexpression sequence is 2.99 E + 08 TU / ml. The SRCIN1 gene therapy vector is delivered to the prefrontal cortex through brain stereotactic injection and is used for up-regulating SRCIN1 expression and improving social behaviors, cognitive functions and anxiety-like behaviors of autism model mice. The SRCIN1 gene therapy vector further comprises an EGFP (enhanced green fluorescent protein) reporter gene which is used for visualizing transfection efficiency. The vector disclosed by the invention is simple to prepare and high in targeting property, and can be used for remarkably improving the social ability and exploration ability of mice, improving infantile autism behaviors such as anxiety behaviors and repeated engraving behaviors of the mice and increasing PSD95 protein expression.

The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I)for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.

The invention provides application of PRP-Exos in preparation of a medicine for treating neuropathic pain, and relates to the technical field of clinical medicine. According to the invention, the treatment effect of PRP-Exos on neuropathic pain by inhibiting a TLR4 / NF-kappa B signal channel is clarified, a new thought is provided for clinical transformation, meanwhile, an intrathecal injection delivery mode is adopted, the limitation of low bioavailability of peripheral administration is overcome, meanwhile, the treatment effect is comprehensively verified through a behavioral-histological-molecular biological multi-modal evaluation system, and the application prospect is wide. The potential of the PRP-Exos in relieving the neuropathic pain is proved.

The invention relates to a method of diagnosing a subtype of autism spectrum disorder (ASD), so called ASD Phenotype 1, by assessing the energy production capacity of patient specific cell lines in presence of various carbon sources of energy and metabolic factors or by assessing the changes in energy production capacity or lack thereof after administration of an Nrf2-inhibitor.

Disclosed is a method of treating a disease or condition characterized by neurodegeneration via administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of hinokitiol, hinokitiol derivatives, and iron-transporting tropolones.

The disclosure relates to, in part, a method of diagnosing whether a patient is afflicted with attention-deficit / hyperactivity disorder (ADHD) and / or selecting ADHD treatment for a patient afflicted with ADHD and / or monitoring response of ADHD symptoms in patient to an ADHD treatment.

The invention belongs to the technical field of medical monitoring and early warning, and relates to an electroencephalogram early warning system for central nervous adverse events in an acupuncture treatment course, and the system comprises an appliance integration and time synchronization association module which is used for synchronously generating an operation mark signal and a skin conductance signal; the reference state vector construction module and the safety stress vector construction module are respectively used for establishing an individualized physiological baseline vector and a safety stress limit vector; the real-time state vector generation module is used for generating a real-time physiological state vector; the dynamic weight adjusting module is used for generating a correction vector; the analysis and risk judgment module is used for analyzing whether the state evolution trajectory meets a risk condition or not; the grading early warning execution module and the intervention instruction triggering module are used for executing grading early warning and closed-loop physical intervention; the technical problems that in an existing acupuncture early warning method, operation and physiological signal time sequence correlation is weak, and multi-system collaborative risk evolution is difficult to comprehensively capture through single-dimension monitoring are solved.

Embodiments of present disclosure provide systems and methods relating to neuromodulation. In particular, the present disclosure provides systems and methods for administering deep brain stimulation (DBS), and for evaluating the efficacy and efficiency of DBS for the treatment of neurological conditions (e.g., Parkinson's disease).

Methods improve cognitive functioning, for example, at least one of episodic memory, executive function, or language skills; supporting memory and / or recall; providing energy and / or ketones to the brain; and / or preventing and / or treating mild cognitive impairment (MCI) in an individual. A composition comprising medium chain triglycerides (MCTs) can be administered to the individual in a daily dosage providing from about 15 g to about 45 g MCTs. The MCTs can include from about 51 wt % to about 90 wt % of octanoic acid. The daily dose can be provided in at least two servings, for example, 2 or 3 servings. Each serving can provide about 15 g MCTs and can include octanoic acid and decanoic acid in a weight ratio of, for example, about 60:about 40. The individual can be 65 years or older and / or have mild cognitive impairment (MCI).

This disclosure relates to the identification of a subset of mGluR network gene CNVs that are predictive of efficacy of treatment with fasoracetam, as well as the identification of an mGluR network gene CNV that is predictive of an increased likelihood of having ADHD as well as having certain symptoms associated with ADHD.

In alternative embodiments, provided are polyheterocyclic uncharged bisoxime antidotes, including polyheterocyclic uncharged bisoximes, and methods for treating, preventing or ameliorating excessive acetylcholine stimulation in the brain comprising administering to an individual in need thereof a polyheterocyclic uncharged bisoxime antidote as provided herein. In alternative embodiments, provided are methods for treating, preventing or ameliorating excessive acetylcholine stimulation in the brain; or, treating, ameliorating or protecting (preventing) an organophosphate toxicity or poisoning or toxic exposure, or for treating, ameliorating or protecting (preventing) organophosphate inhibition of an acetylcholinesterase (AChE) comprising administering to an individual in need thereof a polyheterocyclic uncharged bisoxime antidote as provided herein.

The present invention provides methods and compositions for treating dementia with Lewy bodies.

The invention provides application of dynamic cortex inhibition imbalance in clinical progress prediction of early Parkinson's disease. The key function of bilateral cortex inhibition balance in adjusting the motion compensation ability of the Parkinson's disease in the early stage is clarified. By analyzing the change of the two inhibition pathways, the change of delta SICI ' / LICI' is found to be a sensitive index capable of predicting the disease progress of the patient with the early Parkinson's disease. ROC results show that the delta SICI ' / LICI' has very high discrimination capability in the aspect of predicting disease progression, the area under curve (AUC) is 0.841, the sensitivity is 87.5%, the specificity is 72.73%, and the Eyden index is 0.602. The research of the invention makes deeper understanding of the pathophysiological mechanism of Parkinson's disease, and highlights the importance of cortex inhibition balance in disease evolution. These observations also support the development of more targeted therapeutic interventions to alleviate symptom progression.